As in every joint reimbursement process, the involved countries Belgium and the Netherlands, assessed the eligibility of Hemgenix® for joint negotiations after the recently finalised joint Health Technology Assessment process. Hemgenix® is a one-shot therapy for the treatment of adults with severe and moderately severe haemophilia B, who have not developed inhibitors against factor IX.
Joint drug price negotiations are the preferred approach of both governments after a joint Health Technology Assessment. However, differences in healthcare systems can occasionally present challenges to this process. In this case there is a clear alignment on principles for establishing the willingness to pay, as described in the HTA report. However, the financing of the current SoC, the factor IX products, is organised differently in both countries and therefore resulting in a different outcome of the recommendation for reimbursement. Therefore, the decision was made to proceed individually with the negotiations for Hemgenix®.
Last update: 17 September